Abstract
There is significant experimental evidence implicating the endogenous opioid system (opioid peptides and opioid receptors) with the processes of reward and reinforcement. Indeed, many behaviors associated with reward and reinforcement, for example feeding behavior, are controlled by distinct components of the endogenous opioid system located in relevant brain regions. It has also been shown that regardless of their initial site of action many drugs of abuse, such as morphine, nicotine, cocaine, alcohol and amphetamines, induce an increase in the extracellular concentration of dopamine in the nucleus accumbens. This, increased secretion of dopamine in the nucleus accumbens seems to be a common effect of many drugs of abuse, and it was proposed that may mediate their rewarding and reinforcing properties. Furthermore, activation of μ opioid receptors in the ventral tegmental area, or of μ and δ opioid receptors in the nucleus accumbens enhances the extracellular concentration of dopamine in the nucleus accumbens. Thus, stimulation of the activity of distinct components of the endogenous opioid system either by opioid or by other drugs of abuse, may mediate some of their reinforcing effects. In this review article, a brief description of the endogenous opioid system and its implication in the processes of reward and reinforcement of opioid and other drugs of abuse will be presented. Furthermore, the use of opioid antagonists in the treatment of drug addiction will be discussed. Special emphasis will be given to ethanol addiction, the drug mainly studied in my laboratory.
Current Topics in Medicinal Chemistry
Title: Endogenous Opioids and Addiction to Alcohol and other Drugs of Abuse
Volume: 9 Issue: 11
Author(s): Christina Gianoulakis
Affiliation:
Abstract: There is significant experimental evidence implicating the endogenous opioid system (opioid peptides and opioid receptors) with the processes of reward and reinforcement. Indeed, many behaviors associated with reward and reinforcement, for example feeding behavior, are controlled by distinct components of the endogenous opioid system located in relevant brain regions. It has also been shown that regardless of their initial site of action many drugs of abuse, such as morphine, nicotine, cocaine, alcohol and amphetamines, induce an increase in the extracellular concentration of dopamine in the nucleus accumbens. This, increased secretion of dopamine in the nucleus accumbens seems to be a common effect of many drugs of abuse, and it was proposed that may mediate their rewarding and reinforcing properties. Furthermore, activation of μ opioid receptors in the ventral tegmental area, or of μ and δ opioid receptors in the nucleus accumbens enhances the extracellular concentration of dopamine in the nucleus accumbens. Thus, stimulation of the activity of distinct components of the endogenous opioid system either by opioid or by other drugs of abuse, may mediate some of their reinforcing effects. In this review article, a brief description of the endogenous opioid system and its implication in the processes of reward and reinforcement of opioid and other drugs of abuse will be presented. Furthermore, the use of opioid antagonists in the treatment of drug addiction will be discussed. Special emphasis will be given to ethanol addiction, the drug mainly studied in my laboratory.
Export Options
About this article
Cite this article as:
Gianoulakis Christina, Endogenous Opioids and Addiction to Alcohol and other Drugs of Abuse, Current Topics in Medicinal Chemistry 2009; 9 (11) . https://dx.doi.org/10.2174/156802609789630956
DOI https://dx.doi.org/10.2174/156802609789630956 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Adverse Effects of Smoking on Health Outcomes in Bipolar Disorder: A Review and Synthesis of Biological Mechanisms
Current Molecular Medicine Non-Linear Alteration of Serotonin Transport Availability in Posttraumatic Stress Disorder Measured with 4-[<sup>18</sup>F] ADAM Positron Emission Tomography
Current Molecular Imaging (Discontinued) Moving Beyond Tyrosine Hydroxylase to Define Dopaminergic Neurons for Use in Cell Replacement Therapies for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Role of Neuromodulation and Optogenetic Manipulation in Pain Treatment
Current Neuropharmacology The Endocannabinoid Signaling System: A Potential Target for Next- Generation Therapeutics for Alcoholism
Mini-Reviews in Medicinal Chemistry Is Nicotine Protective Against Parkinson´s Disease? An Experimental Analysis
CNS & Neurological Disorders - Drug Targets What We have Learned about Pain from Rodent Models of Arthritis?
Current Rheumatology Reviews Vanilloid Transient Receptor Potential Cation Channels: An Overview
Current Pharmaceutical Design The Mammalian Tachykinin Ligand-Receptor System: An Emerging Target for Central Neurological Disorders
CNS & Neurological Disorders - Drug Targets Purinergic Receptors and Pain
Current Pharmaceutical Design Diagnosis and Treatment of Paraneoplastic Neurological Syndromes
Current Clinical Pharmacology “Tripping out” with the TRP Superfamily and TRPV1 for Novel Neuroprotection
Current Neurovascular Research Neuropharmacology of Vestibular System Disorders
Current Neuropharmacology Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Prosodic Impairment in Dementia: Review of the Literature
Current Alzheimer Research Novel Potential Therapeutics for Schizophrenia: Focus on the Modulation of Metabotropic Glutamate Receptor Function
Current Neuropharmacology Editorial (Hot Topic: Advances in Dystonia)
Current Neuropharmacology Neurobiological Evidence for the Primacy of Mania Hypothesis
Current Neuropharmacology Preface
Central Nervous System Agents in Medicinal Chemistry Editorial (Hot Topic: Regenerative Medicine in Neurological Diseases)
Recent Patents on Regenerative Medicine